Cargando…

Assessment of costs associated with adverse events in patients with cancer

Adverse event (AE)-related costs represent an important component of economic models for cancer care. However, since previous studies mostly focused on specific AEs, treatments, or cancer types, limited information is currently available. Therefore, this study assessed the incremental healthcare cos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, William, Yim, Yeun Mi, Kim, Ashley, Cloutier, Martin, Gauthier-Loiselle, Marjolaine, Gagnon-Sanschagrin, Patrick, Guerin, Annie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898735/ https://www.ncbi.nlm.nih.gov/pubmed/29652926 http://dx.doi.org/10.1371/journal.pone.0196007

Ejemplares similares

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
por: Gauthier-Loiselle, Marjolaine, et al.
Publicado: (2021)

Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study
por: Schein, Jeff, et al.
Publicado: (2022)

The societal economic burden of autosomal dominant polycystic kidney disease in the United States
por: Cloutier, Martin, et al.
Publicado: (2020)

Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study
por: Schein, Jeff, et al.
Publicado: (2023)

Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis
por: Schein, Jeff, et al.
Publicado: (2023)

Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department
por: Peacock, W. Frank, et al.
Publicado: (2022)

Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States – a retrospective claims analysis
por: Schein, Jeff, et al.
Publicado: (2022)

Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population – a machine learning approach
por: Gagnon-Sanschagrin, Patrick, et al.
Publicado: (2022)

Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review
por: Aigbogun, Myrlene Sanon, et al.
Publicado: (2020)

Impact of agitation in long‐term care residents with dementia in the United States
por: Fillit, Howard, et al.
Publicado: (2021)

Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer’s perspective
por: Hariprasad, Seenu M, et al.
Publicado: (2021)

Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
por: Michalopoulos, Steven N., et al.
Publicado: (2022)

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
por: Tsang, Yuen, et al.
Publicado: (2023)

Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
por: Sargent, Therese, et al.
Publicado: (2023)

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
por: Young, James B., et al.
Publicado: (2018)

Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis
por: Gauthier-Loiselle, Marjolaine, et al.
Publicado: (2021)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States
por: Hernandez-Pastor, Luis, et al.
Publicado: (2023)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Hospital costs associated with adverse events in people with diabetes in the UK
por: Keng, Mi Jun, et al.
Publicado: (2022)

Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
por: Han, Nayoung, et al.
Publicado: (2020)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han, Nayoung, et al.
Publicado: (2021)

Direct medical costs of adverse events in Dutch hospitals
por: Hoonhout, Lilian HF, et al.
Publicado: (2009)

Costs associated with adverse events among acute patients
por: Kjellberg, Jakob, et al.
Publicado: (2017)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
por: Oh, William K., et al.
Publicado: (2017)

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
por: Gauthier, Geneviève, et al.
Publicado: (2017)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs
por: Xu, Yan, et al.
Publicado: (2013)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Clinical assessment of immune-related adverse events
por: Sosa, Aaron, et al.
Publicado: (2018)

The average cost of measles cases and adverse events following vaccination in industrialised countries
por: Carabin, Hélène, et al.
Publicado: (2002)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

How to assess cryoballoon ablation‐related adverse events
por: Kataoka, Naoya, et al.
Publicado: (2023)

Adverse event detection by medical record review is reproducible, but the assessment of their preventability is not
por: Klein, Dorthe O., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ff86jd6c743isg4p2ut07o92sr